| **Oral triple-x (XXX) treatment compared to control for thrombophilia patients****Bibliography: treatment XXX versus control for patients with thrombophilia. Cochrane Database of Systematic Reviews [Year], Issue [Issue].** |
| --- |
| **Quality assessment**  | **Summary of findings**  |
| **№ of participants(studies)Follow-up** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Publication bias** | **Overall quality of evidence** | **Study event rates (%)** | **Relative effect(95% CI)** | **Anticipated absolute effects** |
| **With control** | **With oral triple-x (XXX) treatment** | **Risk with control** | **Risk difference with oral triple-x (XXX) treatment** |
| **mortality (critical) (follow up: mean 12 months)** |
| 2798(5 RCTs)  | serious 1 | not serious  | not serious  | not serious  | none 2 | ⨁⨁⨁◯MODERATE  | 363/1401 (25.9%)  | 346/1397 (24.8%)  | **RR 0.96**(0.85 to 1.09)  | **Study population**  |
| 259 per 1,000  | **10 fewer per 1,000**(39 fewer to 23 more)  |
| **Low**  |
| 150 per 1,000  | **6 fewer per 1,000**(23 fewer to 14 more)  |
| **High**  |
| 350 per 1,000  | **14 fewer per 1,000**(53 fewer to 32 more)  |
| **myocardial infarction (critical) (follow up: mean 12 months)** |
| 3182(6 RCTs)  | not serious  | not serious  | not serious  | not serious  | none  | ⨁⨁⨁⨁HIGH  | 457/1618 (28.2%)  | 349/1564 (22.3%)  | **RR 0.88**(0.79 to 0.99)  | **Study population**  |
| 282 per 1,000  | **34 fewer per 1,000**(59 fewer to 3 fewer)  |
| **Low**  |
| 200 per 1,000  | **24 fewer per 1,000**(42 fewer to 2 fewer)  |
| **symptomatic VTE (critical) (follow up: mean 12 months)** |
| 1129(2 RCTs)  | very serious 1,3 | not serious  | not serious  | serious 4 | none 2 | ⨁◯◯◯VERY LOW  | 170/574 (29.6%)  | 147/555 (26.5%)  | **RR 0.89**(0.72 to 1.08)  | **Study population**  |
| 296 per 1,000  | **33 fewer per 1,000**(83 fewer to 24 more)  |
| **Low**  |
| 200 per 1,000  | **22 fewer per 1,000**(56 fewer to 16 more)  |
| **High**  |
| 400 per 1,000  | **44 fewer per 1,000**(112 fewer to 32 more)  |
| **stroke (critical) (follow up: mean 12 months)** |
| 1723(5 RCTs)  | serious 1 | not serious  | not serious  | serious 5 | none 2 | ⨁⨁◯◯LOW  | 135/862 (15.7%)  | 129/861 (15.0%)  | **RR 0.96**(0.77 to 1.19)  | 157 per 1,000  | **6 fewer per 1,000**(36 fewer to 30 more)  |
| **major bleeding (critical) (follow up: mean 12 months)** |
| 1010(3 RCTs)  | serious 1 | not serious  | not serious  | very serious 5,6 | none 2 | ⨁◯◯◯VERY LOW  | 52/505 (10.3%)  | 57/505 (11.3%)  | **RR 1.05**(0.74 to 1.51)  | 103 per 1,000  | **5 more per 1,000**(27 fewer to 53 more)  |
| **non-ulcer dyspepsia (critical) (follow up: mean 12 months)** |
| 4611(5 observational studies)  | serious 7 | not serious  | not serious  | not serious  | none 2 | ⨁◯◯◯VERY LOW  | 70/2308 (3.0%)  | 118/2303 (5.1%)  | **RR 1.66**(1.19 to 2.31)  | 30 per 1,000  | **20 more per 1,000**(6 more to 40 more)  |
| **minor bleeding (important) (follow up: mean 12 months)** |
| 1204(2 RCTs)  | serious 1 | not serious 8 | not serious  | serious 5 | none 2 | ⨁⨁◯◯LOW  | 40/603 (6.6%)  | 96/601 (16.0%)  | **RR 2.56**(1.33 to 4.92)  | 66 per 1,000  | **103 more per 1,000**(22 more to 260 more)  |
| **thrombosis related pain (follow up: mean 30 days; assessed with: 10-pt visual analog scale (VAS); Scale from: 0 to 10)** |
| 561(3 RCTs)  | not serious  | not serious 9 | not serious  | serious 10 | none 2 | ⨁⨁⨁◯MODERATE  | 268  | 293  | -  | The mean thrombosis related pain was **2.905** point  | MD **0.4 point lower**(0.76 lower to 0.03 lower) 11 |

**CI:** Confidence interval; **RR:** Risk ratio; **MD:** Mean difference

1. ランダム割り付け、割り付けの隠蔽に深刻な限界がある（選択バイアス）
2. メタアナリシスに含められた研究は10件未満であり、出版バイアス評価のためのファンネルプロットは作成できない
3. アウトカムの評価法が不確かである
4. 信頼区間は、”効果なし”と””相当な利益”の双方を含んでいる
5. サンプルサイズがOIS（α0.05、β0.2、RRR=0.25）より少ない
6. CIが”効果なし”と”相当な害”の双方を含んでいる
7. アウトカムの測定が不確かである（上部消化管内視鏡の実施率はわずかに20%）
8. かなりの異質性があるが(I2=63%), 点推定値は同じ方向のため重要性は疑問であることから、グレードダウンとはしない
9. かなりの異質性があるが(I2=73%), 点推定値は同じ方向のため重要性は疑問であることから、グレードダウンとはしない
10. サンプルサイズは、連続アウトカムのOIS基準を満たしていない（Δ=0.2ES）
11. SMD: -0.45(-0.79～-0.12)